Page 186 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 7
Results
Clinical characteristics
From April 2015 to February 2018, 85 patients were included from 20 hospitals in the Netherlands and Belgium.Three patients were declared ineligible (two because the MYC+ status was based on immunohistochemistry and not on FISH and one because of a transformed lymphoma), leaving 82 patients for efficacy and 85 patients for safety analyses. Baseline patient and disease characteristics are shown in Table 1. The median age was 63 years (range: 28-82 years). 49 of 81 patients (60%) had a WHO performance status (PS) of 0; 58 of 71 patients (71%) had stage IV disease, and 42 of 82 patients (51%) had ≥2 extranodal localizations. The IPI score was high-intermediate and high in 65% of patients. During treatment 12 of 82 patients went off protocol before completion (progressive disease [n=7], toxicity [n=2]; pulmonary embolism and diarrhea, other reasons [n=3]; new diagnosis of colon cancer, patient refusal, and vertebral fracture), see Figure 1.
Table 1. Patient demographics and disease characteristics.
Patients completed treatment
Median age (range) in years
Sex
male female
WHO performance status
0 1
23
Prior treatment
no
1 course of R-CHOP only corticosteroids
Ann Arbor stage
II III IV
Extranodal localisations
0 1 ≥2
LDH > ULN
yes
no unknown
N% 82 100 63 (28-82)
56 68 26 32
4960 2632
52 62
1316 68 83 1 1
1215 12 15 5871
3138 911 4251
57 70 2024 5 6
184